Eli Lilly defeats Novo Nordisk attempt to halt weight-loss drug ads

What happened: A US judge denied Novo Nordisk's bid to halt Eli Lilly's weight-loss drug advertisements, which Novo alleged were false and misleading. Key numbers: Judge Zahid Quraishi issued a 25-page decision after a two-day hearing in late August; Novo Nordisk sued in July; ads ran April to July. Why it matters: The judge found Eli Lilly's ads had at most a negligible market impact and Novo's prescriptions stayed stable. Novo said the ruling did not decide whether the ads are false and the litigation continues. Market: +0.5% today ($1,279.14), +18.8% YTD, 0.8x vol — as of 08:30 UTC Verified: Q3_2026 (Oct 29) revenue $21.7B vs $21.7B est; next print ~Jan 28 Coverage: 3 outlets in 24h

A US judge denied Novo Nordisk's bid to halt Eli Lilly's weight-loss drug advertisements, which Novo alleged were false and misleading.

The judge found Eli Lilly's ads had at most a negligible market impact and Novo's prescriptions stayed stable. Novo said the ruling did not decide whether the ads are false and the litigation continues. Market: +0.5% today ($1,279.14), +18.8% YTD, 0.8x vol — as of 08:30 UTC Verified: Q3_2026 (Oct 29) revenue $21.7B vs $21.7B est; next print ~Jan 28